Comparing LD patients with and without complications, we did not find significant differences in LRG1 serum levels between LD patients with insulin resistance (defined as HOMA-IR ≥ 2.5; n = 46) vs. LD patients without insulin resistance (HOMA-IR < 2.5; n = 14; p = 0.327), LD patients with overt diabetes mellitus (n = 38) vs. non-diabetic LD patients (n = 22; p = 0.709), and LD patients with hepatic steatosis (n = 28) vs. no steatosis (n = 20; p = 0.975). This evidence concerns the gene LRG1 and fatty liver disease.